Therapeutic Drug Monitoring in Pregnant Patients.
During pregnancy, there are several physiological changes during each trimester that can affect the absorption, distribution, metabolism, and elimination of drugs. Although, there is a potential need to understand the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs in pregnant patients, therapeutic drug monitoring (TDM) is not well established for various drug classes due to ethical and safety concerns regarding the neonate. Potential risks from in utero drug exposure to the fetus may impact growth and development and may cause malformations or teratogenesis. The clinician must consider the benefits of drug treatment for the pregnant mother versus the risk to the fetus, prior to prescribing medications during pregnancy. The objective of this review is to aid clinicians, pharmacists, and laboratorians in understanding the PK and PD changes during pregnancy, to provide drug class recommendations for monitoring therapy throughout pregnancy via TDM, and to highlight the recent directives of governing agencies on maternal and fetal health.